Genolution Inc. (225220.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩1,711 (+1.30%) as of
Key statistics
- Market cap
- 30.93B
- Dividend yield
- 0.00%
- 52-week range
- 957.00 – 2,300.00
- Beta
- 0.13
- Revenue (TTM)
- 10.03B
- Profit margin
- -46.46%
- Volume
- 26.65k
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 72
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.